IPAV is pleased to announce that key team members will be presenting at the Terra Pinn US Regenerative Medicine Congress in Washington DC, USA, attempting to ‘Demystify Regenerative Medicine Intellectual Property.’
Managing Partners, David Brindley and Ian Bingham, will be joined by Advisory Board member Rebecca Buzzeo, leading a discussion of the unique issues facing academics and industrialists seeking to drive the clinical development and adoption of regenerative therapeutics. The discussion is likely to focus on key trends such as:
- Where is the critical IP in regenerative medicine – product or process?
- What to patent or not to patent – trade secrets versus formal IP?
- How can clinical trial strategy be aligned to support the extension of IP protection?
We hope that you can join us in DC. Should you wish to register for the event, please contact email@example.com.